Sanofi Says amlitelimab Met Primary And Secondary Endpoints In Coast 1 Phase 3 Study

Sanofi SA SAN:

• SANOFI’S AMLITELIMAB MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS IN THE COAST 1 PHASE 3 STUDY IN ADULTS AND ADOLESCENTS WITH ATOPIC DERMATITIS

• AMLITELIMAB MEETS PRIMARY AND SECONDARY ENDPOINTS IN PHASE 3 STUDY

• FULL RESULTS TO BE SUBMITTED FOR PRESENTATION AT MEDICAL MEETING

• AMLITELIMAB SHOWS SIGNIFICANT EFFICACY IN SKIN CLEARANCE AT WEEK 24

• AMLITELIMAB UNDER CLINICAL INVESTIGATION, NOT EVALUATED BY REGULATORY AUTHORITY